gatifloxacin has been researched along with Bronchitis, Chronic in 3 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Bronchitis, Chronic: A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BMS and BAL were used to analyze the pharmacokinetics of gatifloxacin in bronchial ELF from healthy young adult subjects and adult patients with chronic bronchitis." | 9.12 | Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage. ( Ishizaka, A; Kikuchi, E; Kikuchi, J; Nishimura, M; Yamazaki, K, 2007) |
| "Gatifloxacin was generally well tolerated, and the majority of adverse events were mild to moderate; only 11 drug-related adverse events in 10 patients (0." | 5.31 | Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis. ( Anzueto, A; Gotfried, M; Nicholson, SC; Russo, R; Wikler, MA, 2002) |
| "BMS and BAL were used to analyze the pharmacokinetics of gatifloxacin in bronchial ELF from healthy young adult subjects and adult patients with chronic bronchitis." | 5.12 | Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage. ( Ishizaka, A; Kikuchi, E; Kikuchi, J; Nishimura, M; Yamazaki, K, 2007) |
| "Gatifloxacin was generally well tolerated, and the majority of adverse events were mild to moderate; only 11 drug-related adverse events in 10 patients (0." | 1.31 | Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis. ( Anzueto, A; Gotfried, M; Nicholson, SC; Russo, R; Wikler, MA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anzueto, A | 1 |
| Gotfried, M | 1 |
| Wikler, MA | 1 |
| Russo, R | 1 |
| Nicholson, SC | 1 |
| Solèr, M | 1 |
| Lode, H | 1 |
| Baldwin, R | 1 |
| Levine, JH | 1 |
| Schreurs, AJ | 1 |
| van Noord, JA | 1 |
| Maesen, FP | 1 |
| Zehrer, M | 1 |
| Kikuchi, J | 1 |
| Yamazaki, K | 1 |
| Kikuchi, E | 1 |
| Ishizaka, A | 1 |
| Nishimura, M | 1 |
2 trials available for gatifloxacin and Bronchitis, Chronic
| Article | Year |
|---|---|
Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Bacteria | 2003 |
Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Area Under Curve; Bronchitis, Chronic; Bro | 2007 |
1 other study available for gatifloxacin and Bronchitis, Chronic
| Article | Year |
|---|---|
Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis, Chronic; Female; Fluoroquinolones | 2002 |